<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most chemotherapeutics harm <z:mpath ids='MPATH_458'>normal</z:mpath> cells causing severe side effects and induce the development of resistance in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Antimicrobial <z:chebi fb="7" ids="16670">peptides</z:chebi> (<z:chebi fb="47" ids="16027,28971">AMPs</z:chebi>), recognized as anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> agents, may overcome these limitations </plain></SENT>
<SENT sid="2" pm="."><plain>The most studied mechanism underlying multi-drug resistance (<z:chebi fb="14" ids="53218">MDR</z:chebi>) is the over-expression of cell membrane transporter P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (P-gp), which extrudes a variety of hydrophobic drugs </plain></SENT>
<SENT sid="3" pm="."><plain>Additionally, P-gp contributes to cell membrane composition and increases the net negative charge on cell surface </plain></SENT>
<SENT sid="4" pm="."><plain>We postulated that NK-<z:chebi fb="0" ids="25094">lysin</z:chebi> derived cationic <z:chebi fb="7" ids="16670">peptide</z:chebi> NK-2 might discriminate and preferentially eliminate P-gp over-expressing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>To test this hypothesis, we employed <z:chebi fb="14" ids="53218">MDR</z:chebi> non-small cell <z:mp ids='MP_0008714'>lung carcinoma</z:mp> (NCI-H460/R) and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (DLD1-TxR) cell lines with high P-gp expression </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="14" ids="53218">MDR</z:chebi> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells that survived NK-2 treatment had decreased P-gp expression and were more susceptible to <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>We found that NK-2 more readily eliminated P-gp high-expressing cells </plain></SENT>
<SENT sid="8" pm="."><plain>Acting in 'carpet-like' manner NK-2 co-localized with P-gp on the <z:chebi fb="14" ids="53218">MDR</z:chebi> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell membrane </plain></SENT>
<SENT sid="9" pm="."><plain>The inhibition of P-gp reduced the NK-2 effect in <z:chebi fb="14" ids="53218">MDR</z:chebi> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and, vice versa, NK-2 decreased P-gp transport activity </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, NK-2 could modulate <z:chebi fb="14" ids="53218">MDR</z:chebi> in unique way, eliminating the P-gp high-expressing cells from <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and making them more vulnerable to classical drug treatment </plain></SENT>
</text></document>